Terry Heiman-Patterson, MD, Director of the Temple MDA/ALS Center of Hope, offered insight to Neurology Today about the news that the 48-week randomized, placebo-controlled phase 3 PHOENIX trial on Relyvrio did not meet its primary and secondary endpoints. The clinical trial had enrolled 664 adults with amyotrophic lateral sclerosis, or ALS.
Temple Faculty Physicians is experiencing technical issues with phone lines. If you are experiencing an emergency, please visit your nearest emergency room. If you would like to schedule an appointment with your provider or have general questions or requests, please contact us by using myTempleHealth.
myTempleHealth
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH